Pune, June 27, 2019 (GLOBE NEWSWIRE) -- Targeted segment is forecast to emerge dominant among various therapies in the Lung Cancer Therapeutics Market, finds Fortune Business Insights in a new study. The study is titled “Lung Cancer Therapeutics Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2026.” According to the study, the Lung Cancer Therapeutics Market will exhibit an exponential CAGR of 13.0% to reach a value of US$ 48,725.9 Mn by 2026 from US$ 18,327.6 Mn in 2018.
Lung cancer is considered one of the leading causes of death by cancer.Cancer can be a result of continuous exposure to asbestos, and unhealthy lifestyle that includes habits such as pipe smoking, cigarette smoking, cigar smoking. The rising incidence of lung cancer is subsequenetly fuelling demand for various therapies in the Lung Cancer Therapeutics Market.Targeted therapy is expected to emerge dominant among other therapies such as vaccine therapy, radiation therapy, chemotheraoy, surgery, and immunotherapy. targeted therapy segment accounted for a share of 51.1% in the year 2018. This is because of the rise in focus towards the diagnosis of lung cancer and positive outcome of targeted therapy that is increasing its demand in the global market.
However, the immunotherapy segment is anticipated to grow at the fastest CAGR during the forecast period. This is because of the rise in the number of product launches related to treating lung cancer. The availability of abundant resources is creating new opportunities of growth in the market during the coming years.
Increasing Investments in Research and Development Activities to Boost Market
Various factors are responsible for boosting the Lung Cancer Therapeutics Market. One among them is the launch of cancer awareness programs by both government and non-government organizations around the world. Cancer awareness and various treatment measures are increasing the demand for cancer therapeutics especially in developing nations. Besides this, increasing investment by market players in research and development activities to discover novel therapeutics is driving the global market.
On the flip side, most of the anticipated drugs for lung cancer are still in their early testing stage and might take some time before finally getting launched in the market. This gestation gap between clinical trial and final launch might create uncertainty among players, making them skeptical about further investments in lung cancer treatment researches. This may hamper the market growth during the forecast period.
Furthermore, Cure for certain type of cancer is yet to be discovered. The cure is yet to be discovered as targeted therapies have no effect on such cancer types. This is more likely to create challenges for the global market for lung cancer therapeutics during the forecast period.
Asia Pacific to Emerge as Fastest Growing Region with Rise in Cancer Awareness Programs
North America is expected to dominate the global market for lung cancer therapeutics. In 2018 the region generated a revenue of US$ 8,093.2 Mn. Growth in this region is attributable to the rising prevalence and diagnostics of lung cancer and the increasing adoption of advanced lung cancer therapeutics. Besides this, increasing awareness about cancer is enabling the market in Asia Pacific exhibit a faster CAGR.
Speak to Analyst https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/lung-cancer-therapeutics-market-100473
A few novel therapeutics are introduced in the market, impelling leading players to research on improved medication. For instance, Genentech, a company operating in the lung cancer therapeutics market has recently launched their new drug named, Alecensa (alectinib), in order to treat ALK-positive non-small cell lung cancer. Such strategies adopted by players will bode well for the Lung Cancer Therapeutics Market in the long run.
Key Companies Covered
- Genentech (F. Hoffmann-La Roche Ltd)
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca
- Pfizer Inc.
- Sanofi
- Novartis AG
- Astellas
- Bristol Myers Squibb
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Millennium Pharmaceuticals, Inc. (Takeda)
- Merck Sharp & Dohme Corp.
- Other players
Browse Complete Report Details Enabled with Complete Tables and Figures:
https://www.fortunebusinessinsights.com/industry-reports/lung-cancer-therapeutics-market-100473
Table of Content:
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence of Lung Cancer by Key Countries
- Regulatory Scenario by Key Regions
- Key Industry Developments
- Overview of Current Advances in R&D for Lung Cancer Therapeutics
- Pipeline Analysis
- Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Therapy
- Targeted Therapy
- Bevacizumab
- Dabrafenib/Trametinib
- Erlotinib Hydrochloride
- Osimertinib
- Others
- Immunotherapy
- Durvalumab
- Nivolumab
- Atezolizumab
- Pembrolizumab
- Chemotherapy
- Targeted Therapy
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis, Insights and Forecast – By Cancer Type
- Non-small cell lung cancer (NSCLC)
- Small cell lung cancer (SCLC)
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Key Findings / Summary
- Competitive Analysis
- Strategic Recommendations
Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/lung-cancer-therapeutics-market-100473
Browse Related Reports:
- Non-Small Cell Lung Cancer Therapeutics Market Size, Share and Global Trend by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Cancer Type (Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma), and Geography Forecast till 2026
- Breast Cancer Therapeutics Market Size, Share and Global Trend By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Cancer Type (Hormone Receptor, HER2+), and Geography Forecast till 2026
- Immunoglobulins Market Size, Share and Global Trend By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liquid, Lyophilized), By End User(Hospitals, Clinics, Homecare) and Geography Forecast till 2026
- Immunology Market Size, Share and Global Trend By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressants, Polyclonal antibody (pAb) ), By Disease Indication ( Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection ), By Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Geography Forecast till 2025
About us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US :+1-424-253-0390
UK :+44-2071-939123
APAC :+91-744-740-1245
Email: sales@fortunebusinessinsights.com
Website: https://www.fortunebusinessinsights.com
Attachment